Rubaiya Tripty of DOT
 Researchers have reanalyzed the Oxford-AstraZeneca vaccine trial findings, this time with an additional month of data. They confirm that the vaccine is safe and effective, just as the interim analysis had suggested. Medical News Today
 The research, published in The Lancet, will help inform health policy as governments weigh the urgency of offering both doses against the relative scarcity of vaccine supplies.
 The government of the United Kingdom decided to leave a 12-week interval between doses of the Oxford-AstraZeneca vaccine. A new analysis of trial data suggests that a 12-week gap “might” be more effective than shorter intervals.
 Meanwhile, The European Medicines Agency’s (EMA) approval for the vaccine is based on the second dose being administered between four and 12 weeks after the first. A 16-week interval has not been tested in any human trials.Reuters
 Spain is the first country to diverge from the European Medicines Agency’s (EMA) authorisation and promote “off label use”, which would not be approved by the regulator and would leave individual nations responsible for any possible side-effects.